ERP015655 PRJEB14050 A_strategic_vision_to_drive_the_control_of_enteric_fever_through_vaccination_-sc-4227 A_strategic_vision_to_drive_the_control_of_enteric_fever_through_vaccination_-sc-4227 A_strategic_vision_to_drive_the_control_of_enteric_fever_through_vaccination_ The overall aim of the Wellcome Trust STRATAA (Strategic Typhoid Alliance across Africa and Asia) project is to provide the science to underpin the implementation of new vaccines for the control of enteric (typhoid) fever, uniquely, in different epidemiological settings in Africa and Asia. The project will: • Provide missing data on disease burden, antibiotic resistance and transmission needed to support and implement conjugate vaccines for enteric fever, using epidemiological data collection and application of knowledge from (para)typhoid human challenge models. • Establish the host-factors that determine susceptibility to enteric fever to inform vaccine implementation strategies. • Provide a comprehensive approach to diagnostics to allow a more accurate assessment of disease burden, vaccine impact and to inform epidemiological models. • Investigate the mechanisms of natural and vaccine-induced protection in human challenge models (UK), test in human-to-mouse studies, and validate in field settings (Nepal, Bangladesh and Malawi) and to develop correlates of protection to drive vaccine implementation. • Model disease dynamics and the balance between direct and indirect vaccine impact in different settings using the biological and epidemiological data emerging from the programme. • Strengthen research capacity in enteric fever endemic regions of the world and provide the data for vaccine implementation advocacy. The overall aim of this WT Strategic Award is to provide the science to underpin the implementation of new vaccines for the control of typhoid fever in different epidemiological settings in Africa and Asia. This will be achieved be establishing a trio of prospective surveillance studies conducted in Dhaka (Bangladesh), Blantyre (Malawi) and Kathmandu (Nepal) including population-based serosurveys, clinical surveillance for typhoid fever, and screening for chronic typhoid carriage. All bacterial isolates collected during the study, i.e. the typhoid agents Salmonella enterica serovars Typhi and Paratyphi A (estimate n=2400), will be whole-genome sequenced (multiplex Illumina HiSeq) in order to (a) investigate the strains and antibiotic resistance determinants circulating in each site, and (b) assess transmission dynamics within and between sites. In addition, 200 isolates from each study site collected prior to the commencement of STRATAA will be sequenced to provide historical context for the currently circulating bacterial populations (total n=3000). This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria) please see http://sanger.ac.uk/datasharing/ ENA-FIRST-PUBLIC 2017-02-14 ENA-LAST-UPDATE 2016-05-16